Sustained remission after ruxolitinib and chimeric antigen receptor T‐cell therapy bridged to a second allogeneic hematopoietic stem cell transplantation for relapsed Philadelphia chromosome‐like B‐cell precursor acute lymphoblastic leukemia with novel NPHP3‐JAK2 fusion